Dihydrotestosterone-transdermal

Drug Profile

Dihydrotestosterone-transdermal

Alternative Names: DHT-transdermal - Bentley

Latest Information Update: 09 Mar 2010

Price : $50

At a glance

  • Originator Bentley Pharmaceuticals
  • Developer Auxilium Pharmaceuticals; Bentley Pharmaceuticals
  • Class Androstanols; Testosterone congeners
  • Mechanism of Action Testosterone agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Male osteoporosis

Most Recent Events

  • 12 Mar 2003 No development reported for Male osteoporosis in USA (Transdermal)
  • 08 Aug 2001 Investigation in Male osteoporosis in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top